Company Profile
Ascentage Pharma Group International, a clinical-stage biotechnology company develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.
The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors.
Its portfolio also includes APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies, and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma.
Additionally, it is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection APG-5918, an orally available and selective embryonic ectoderm development inhibitor.
Additionally, it is involved in medical R&D. Its portfolio also includes clinical development, clinical trials operations, venture capital investment, rental of buildings, and provision of science and technology promotion services.
The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Founded in 2009, Ascentage Pharma Group International is headquartered in Suzhou, China.